Haleon And 2 British AI Healthcare Stocks To Watch Sasha Jovanovic Sun, October 18, 2026 at 4:09 AM EDT 5 min read HLN +1.91% MSFT -1.93% AZN -0.76% ABDX.L 0.00% HLN +1.91% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
America's vast AI infrastructure build is starting to look more fragile, and that matters for UK investors watching where the real value sits in artificial intelligence. Hardware projects can stall when financing or public support weakens. Software that helps doctors work faster and make better calls in hospitals can keep scaling with fewer physical bottlenecks. This article highlights three UK listed AI driven healthcare stocks from our screener.
The three stocks in this article are just a sample from the wider opportunity set, and the full screen surfaced 5 more listed healthcare AI players with equally compelling narratives that are not covered below. To identify which ones best fit your own thesis, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter, analyze, and focus on the highest conviction ideas.
Haleon brings the AI theme into everyday healthcare, using Microsoft powered data tools to fine tune product development and consumer targeting while still relying on its large over the counter portfolio for most of the heavy lifting.
Haleon sells over the counter consumer health brands across oral care, pain relief, respiratory and vitamins, while using a Microsoft partnership to build AI driven digital and data capabilities. Revenue is spread across North America at about £3.8b, APAC at roughly £2.6b and EMEA and Latam at about £4.7b. The group is valued at around £33b by the market.
"Extending the current productivity and AI programme, which has already delivered 140 basis points of gross margin improvement alongside SKU and formulation reduction, provides room for further structural cost savings. That could widen net margins and raise free cash flow beyond what is implied by modest top line growth."
What happens if one quiet shift in how Haleon allocates those savings starts to change the balance between volume growth and pricing power.
That capital shift is the crux of the full narrative for Haleon, where the trade off between pricing, volume and AI driven efficiencies looks far more nuanced than the headline story suggests.
Abingdon Health uses its Appdx smartphone reader and digital health tools to integrate AI into everyday diagnostics, while most income still comes from contract development and regulatory work. Contract development generates about £5 million, regulatory services £4.1 million, with a market value near £39 million.
For investors tracking how AI is changing diagnostics at the point of care, Abingdon Health connects that shift to the very practical question of how a test strip is read and turned into usable data.
"Broader adoption of rapid point of care and self testing across multiple therapy areas is creating more demand for lateral flow based companion diagnostics. Abingdon's end to end CDMO and regulatory capabilities can support larger, longer duration programs and potentially raise revenue visibility and earnings quality."
The business impact may depend on what happens if a relatively quiet change in how those longer contracts are priced begins to reshape the balance between volume work and higher margin digital services.
As that pricing mix quietly shifts, read the full narrative for Abingdon Health to see how contract structure, AI tools and recurring digital work could be accelerating beneath the surface.
AstraZeneca is a global biopharma heavyweight focused on prescription medicines, with oncology at the front of its AI story. The group is weaving multimodal cancer data partnerships into a broad drug portfolio while generating about $61.4b from pharmaceuticals and carrying a market value near £193b.
AstraZeneca gives this screener a large cap anchor, using AI not as a separate product line but as a tool inside its oncology and drug development engine. That is exactly where the biggest healthcare impact is likely to show up.
"Ongoing investments in transformative technologies (such as next-generation ADCs, bispecific antibodies, mRNA platforms, and AI/digital-enabled clinical trial efficiencies) are expected to accelerate drug development cycles, enable precision medicine launches, and support higher net margins due to more efficient R&D and premium pricing potential."
What really shifts the dial is what happens if one pressure point in that oncology led model meaningfully changes the future margin profile investors are assuming.
If that pressure point is what decides where the real upside sits, the full narrative for AstraZeneca shows how AstraZeneca's oncology engine, capital allocation and AI bets could be quietly decoupling from expectations.
Fresh ideas move first. Breakout stories gain momentum while others are still caught looking at yesterday's winners. Some will be flying under the radar for now, so act now.
Target resilient compounding by scanning a curated 4 resilient stocks with low risk scores that can help keep you engaged even if momentum suddenly drops elsewhere.
Track real-world infrastructure demand with a focused 42 power grid technology and infrastructure stocks and spot businesses that may benefit as electrification spending increases.
Focus on real earnings potential rather than hype by reviewing 39 profitable AI stocks that aren't just burning cash while the most cash generative AI stories are still at an earlier stage.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
